Most recent update: Friday, April 3, 2020 - 08:40

Bariatric News - Cookies & privacy policy

You are here


Oral semaglutide vs sitagliptin has superior reductions in HbA1c and weight

Oral semaglutide 7mg and 14mg demonstrated superior HbA1c and body weight reductions compared to Januvia (sitagliptin 100mg), although non-inferiority for oral semaglutide 3mg for HbA1c reductions at 26 weeks was not confirmed.

Semaglutide safe and effective against type 2 diabetes

Semaglutide is safe and effective for the treatment of type 2 diabetes, according to a review by researchers from the Aristotle University of Thessaloniki, Greece. The researchers found that semaglutide is a potent once‐weekly GLP‐1 RA, reducing significantly HbA1c, body weight and systolic blood pressure. However, they noted semaglutide was associated with increased incidence of gastrointestinal adverse events.

Levels of kynurenine metabolites substantially decreased post-op

Plasma levels of the kynurenine (3-hydroxykynurenine and 3-hydroxyanthranilic acid) metabolites were substantially decreased, along with a metabolic improvement one year after bariatric surgery, according to a study published by researchers from Norway. The stated that their study examining the role of kynurenine metabolites in the pathophysiologic pathways leading to metabolic impairment in individuals with obesity warrants further investigation.

Subscribe to RSS - HbA1c